Treating gout in kidney transplant recipients

Progress in Transplantation

Volumn 14, Issue 2, 2004, Pages 143-147

  Baroletti, Steven ^a   Bencivenga, Gina ^b   Gabardi, Steven ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE DISEASE; CLASSIFICATION; DRUG ADMINISTRATION; EPIDEMIOLOGY; GOUT; HUMAN; HYPERURICEMIA; KIDNEY TRANSPLANTATION; MEAT; METHODOLOGY; PRACTICE GUIDELINE; PREVALENCE; PROTEIN RESTRICTION; REVIEW; SEA FOOD; UNITED STATES;

ACUTE DISEASE; CAUSALITY; DIET, PROTEIN-RESTRICTED; DRUG ADMINISTRATION SCHEDULE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MEAT; PRACTICE GUIDELINES; PREVALENCE; SEAFOOD; UNITED STATES;

EID: 6944240358     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.14.2.dr3j76l1603k0145     Document Type: Article

References (30)

1. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003. Available at: Http://www.unos.org. Accessed February 20, 2004.
2. Abdelrahman M, Rafi A, Ghacha R, Youmbissi JT, Qayyum T, Karkar A. Hyperuricemia and gout in renal transplant recipients. Ren Fail. 2002;24:361-367. (Pubitemid 34839957)
3. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-979. (Pubitemid 30241734)
4. Harris M, Siegel L, Alloway J. Gout and hyperuricemia. Am Fam Phys. 1999;59:925-934. (Pubitemid 29108611)
5. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: Risks and consequences in the normative aging study. Am J Med. 1987;82:421-426.
6. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med. 1979;67:74-82. (Pubitemid 9230708)
7. Peeters P, Sennesael J. Low-back pain caused by spinal tophus-a complication of gout in a kidney transplant recipient. Nephrol Dial Transplant. 1998;13:3245-3247. (Pubitemid 28534747)
8. Better OS. Tubular dysfunction following kidney transplantation. Nephron. 1980;25:209-213. (Pubitemid 10095803)
9. Hollander A, van Saase J, Kootte A, et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet. 1995;345:610-614.
10. Lin H, Rocher L, McQuillan M, Schmaltz S, Palella T, Fox I. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321:287-292. (Pubitemid 19193803)
11. Gores P, Fryd D, Sutherland D, Najarian J, Simmons R. Hyperuricemia after renal transplantation. Am J Surg. 1988;156:397-400. (Pubitemid 19009747)
12. Marcen R, Gallego N, Orofino L, et al. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron. 1995;70:307-313.
13. Pilmore HL, Faire B, Dittmer I. Tacrolimus for the treatment of gout in renal transplantation: Two case reports and review of the literature. Transplantation. 2001;72:1703-1705. (Pubitemid 33096751)
14. Jarowenko MK, Flechner SM, van Buren CT, Lorber MI, Kahan BD. Influence of cyclosporin on post transplant blood pressure response. Am J Kidney Dis. 1987;10:98.
15. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int. 1998;53:217-222. (Pubitemid 28066925)
16. Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
17. Olyaei A. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999;58:1011-1027. (Pubitemid 30055044)
18. Delaney V, Sumrani N, Daskalakis P, Hong JH, Sommer BG. Hyperuricemia and gout in renal allograft recipients. Transplant Proc. 1992;24:1772-1774.
19. Drugdex System [computer program]. Vol 117. Greenwood Village, Colo: Micromedex; 2004.
20. Braun WE. Modification of the treatment of gout in renal transplant recipients. Transplant Proc. 2000;32:199. (Pubitemid 30100810)
21. Dupont P, Hunt I, Goldberg L, Warrens A. Colchicine myoneu - ropathy in a renal transplant patient. Transpl Int. 2002; 15:374-376. (Pubitemid 36068192)
22. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med. 1984;310: 563-572.
23. Palmer BF. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Invest Med. 1995:43:516.
24. Schneider A, Stahl R. Cyclooxygenase-2 (COX-2) and the kidney: Current status and potential perspectives. Nephrol Dial Transplant. 1998;13:10-12. (Pubitemid 28033568)
25. Jacobs F, Mamzer-Bruneel MF, Skhiri H, Thervet E, Legendre CH, Kreis H. Safety of the mycophenolate mofetilallopurinol combination in kidney transplant recipients with gout. Transplantation. 1997;64:1087-1088. (Pubitemid 27446781)
26. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: A potentially dangerous combination. J Intern Med. 1990;228:69-71. (Pubitemid 20221943)
27. Wortmann RL. Effective management of gout: An analogy. Am J Med. 1998;105:513-514. (Pubitemid 29013338)
28. Catalano C, Fabbian F, Bordin V, Di Landro D. Mycophenolate mofetil toxicity in an anorexic kidney transplant patient treated with sulphinpirazone. Nephrol Dial Transplant. 1997;12:2467-2468. (Pubitemid 27474654)
29. Baroletti S, Gabardi S, Magee C, Milford E. Calcium channel blockers as treatment of choice in renal transplant recipients: Fact or fiction. Pharmacotherapy. 2003;23:788-801. (Pubitemid 36629082)
30. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril, alone or with a diuretic on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int. 2000;58:762-767.